-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Through Thick and Thin: Confronting the Aggressive Cutaneous T-cell Lymphomas

Program: Education Program
Session: Addressing Unmet Needs in T Cell Lymphomas
Hematology Disease Topics & Pathways:
Clinical Practice (Health Services and Quality), Education, Study Population, Human
Monday, December 9, 2024, 4:30 PM-5:45 PM

Steven Horwitz, MD

Memorial Sloan-Kettering Cancer Center, New York, NY

Disclosures: Horwitz: Auxilius Pharma, Abcuro Inc., Corvus, Daiichi Sankyo, DrenBio, Farallon Capital Management, L.L.C., Kyowa Hakko Kirin, March Bio, Neovii Pharmaceuticals AG, ONO Pharmaceuticals, Pfizer, SecuraBio, SymBio, Treeline Bio and Takeda Pharmaceuticals.: Consultancy; ADC Therapeutics, Affimed, Celgene, Crispr Therapeutics, Daiichi Sankyo, Kyowa Hakko Kirin, Takeda, Seattle Genetics, Trillium Therapeutics, and SecuraBio.: Research Funding; Auxilius Pharma, Abcuro Inc., Corvus, CTI BioPharma Corp, Daiichi Sankyo, DrenBio, Kyowa Hakko Kirin, March Bio, ONO Pharmaceuticals, Pfizer, SecuraBio, SymBio and Takeda Pharmaceuticals.: Honoraria.

See more of: Addressing Unmet Needs in T Cell Lymphomas
See more of: Education Program
<< Previous Presentation | Next Presentation >>